Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.30 is 25% above its 5-year average of -0.40, near the high end of its 5-year range (-0.46–-0.30).
17.81% above its 12-month average of -0.36.
Reported quarterly EPS; no daily interpolation. Q3 FY2026 (2026-07-31): -0.08.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T19:35:39.516Z. Historical observations retain their original dates. Historical series through 2026-01-12.
EARNINGS PER SHARE (EPS)
-0.30
EARNINGS PER SHARE (EPS) AVG TTM
-0.36
EARNINGS PER SHARE (EPS) AVG 3Y
-0.38
EARNINGS PER SHARE (EPS) AVG 5Y
-0.40
EARNINGS PER SHARE (EPS) AVG 10Y
-0.45
EARNINGS PER SHARE (EPS) AVG 15Y
-0.59
EARNINGS PER SHARE (EPS) AVG 20Y
-0.73
CURRENT VS TTM AVG
+17.81%
CURRENT VS 3Y AVG
+20.00%
CURRENT VS 5Y AVG
+25.31%
CURRENT VS 10Y AVG
+33.06%
CURRENT VS 15Y AVG
+49.10%
CURRENT VS 20Y AVG
+58.90%
Anixa Biosciences, Inc.
Market Cap
$102.92M
Earnings Per Share (EPS)
-0.30
TTM Avg
-0.36
3Y Avg
-0.38
5Y Avg
-0.40
Market Cap
$103.68M
Earnings Per Share (EPS)
-0.12
TTM Avg
-0.17
3Y Avg
-0.12
5Y Avg
-0.12
Market Cap
$104.00M
Earnings Per Share (EPS)
-0.74
TTM Avg
-0.44
3Y Avg
-1.32
5Y Avg
-1.80
Market Cap
$104.21M
Earnings Per Share (EPS)
-1.60
TTM Avg
-2.42
3Y Avg
-1.68
5Y Avg
-1.45
Market Cap
$101.28M
Earnings Per Share (EPS)
0.27
TTM Avg
-0.10
3Y Avg
-0.20
5Y Avg
0.10
Market Cap
$106.18M
Earnings Per Share (EPS)
-4.80
TTM Avg
-8.13
3Y Avg
-18.81
5Y Avg
-23.77
Market Cap
$106.33M
Earnings Per Share (EPS)
-6.48
TTM Avg
-4.79
3Y Avg
-7.51
5Y Avg
-13.98
Market Cap
$107.43M
Earnings Per Share (EPS)
-1.87
TTM Avg
-4.43
3Y Avg
-5.52
5Y Avg
-12.34
Market Cap
$98.41M
Earnings Per Share (EPS)
-3.50
TTM Avg
-4.18
3Y Avg
-3.30
5Y Avg
-7.15
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anixa Biosciences, Inc. (ANIX) | $102.92M | -0.30 | -0.36 | -0.38 | -0.40 |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $103.68M | -0.12 | -0.17 | -0.12 | -0.12 |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $104.00M | -0.74 | -0.44 | -1.32 | -1.80 |
| Definitive Healthcare Corp. (DH)vs › | $104.21M | -1.60 | -2.42 | -1.68 | -1.45 |
| The Joint Corp. (JYNT)vs › | $101.28M | 0.27 | -0.10 | -0.20 | 0.10 |
| Immunic, Inc. (IMUX)vs › | $106.18M | -4.80 | -8.13 | -18.81 | -23.77 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $106.33M | -6.48 | -4.79 | -7.51 | -13.98 |
| Outlook Therapeutics, Inc. (OTLK)vs › | $107.43M | -1.87 | -4.43 | -5.52 | -12.34 |
| OnKure Therapeutics, Inc. (OKUR)vs › | $98.41M | -3.50 | -4.18 | -3.30 | -7.15 |
| PolyPid Ltd. (PYPD)vs › | $97.52M | -1.48 | -3.50 | -21.30 | -30.60 |
Trailing EPS (TTM)
$-0.30
Forward EPS (Est.)
$-0.32
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-10-31 | -0.34 |
| 2024-10-31 | -0.39 |
| 2023-10-31 | -0.32 |
| 2022-10-31 | -0.45 |
| 2021-10-31 | -0.45 |
| 2020-10-31 | -0.46 |
| 2019-10-31 | -0.61 |
| 2018-10-31 | -0.79 |
| 2017-10-31 | -0.41 |
| 2016-10-31 | -0.57 |
| 2015-10-31 | -0.14 |
| 2014-10-31 | -1.00 |
| 2013-10-31 | -1.17 |
| 2012-10-31 | -0.53 |
| 2011-10-31 | -1.01 |
| 2010-10-31 | -0.79 |
| 2009-10-31 | -2.70 |
| 2008-10-31 | -1.02 |
| 2007-10-31 | -1.20 |
| 2006-10-31 | -1.81 |
| 2005-10-31 | -1.14 |
| 2004-10-31 | -0.92 |
| 2003-10-31 | -0.94 |
| 2002-10-31 | -1.10 |
| 2001-10-31 | -1.26 |
| 2000-10-31 | -1.81 |
| 1999-10-31 | -3.29 |
| 1998-10-31 | -2.79 |
| 1997-10-31 | -2.29 |
| 1996-10-31 | -2.24 |
